3. M essag e Fro m
The P res id ent,
M offitt Med ical G ro u p
Dear Colleague,
This Guide for Referring Physicians has been developed to assist you in accessing the
resources and services at the H. Lee Moffitt Cancer Center & Research Institute that are
available to you and your patients.
Moffitt Medical Group physicians, scientists, and staff members continue to fight on all fronts
to “contribute to the prevention and cure of cancer,” which is Moffitt’s mission. We consider
it a privilege to participate in the care of your patients, and it is our goal to complement the
services you provide in the community.
At Moffitt Cancer Center, our clinical services have been organized into disease-oriented
interdisciplinary programs. This guide contains overviews of Moffitt’s clinical programs and
services and information on how to contact each program.
We hope you find this directory useful, and we invite you to call on the clinical, research and
educational resources at Moffitt Cancer Center. If you have questions or concerns that are not
being addressed by our faculty or staff, please do not hesitate to call me at 813-745-6086.
Alan F. List, MD
Executive Vice President, Clinical Sciences
Physician-In-Chief
President, Moffitt Medical Group
3
4. Ta b l e O f Co nte nts
How To Refer A Patient 5
Moffitt Cancer Center Adds Location
Near International Plaza 6
Interdisciplinary Clinical Programs And Services:
Blood And Marrow Transplant Program 8
Breast Program 9
Cutaneous Oncology Program 10
Endocrine Tumor Program 11
Gastrointestinal Oncology Program 12
Genitourinary Oncology Program 13
Gynecologic Oncology Program 14
Head And Neck Oncology Program 15
Internal And Hospital Medicine Program 16
Malignant Hematology Program 17
Neuro-Oncology Program 18
Psychosocial And Palliative Care Program 19
Radiation Oncology Department 20
Sarcoma Program 21
Senior Adult Oncology Program 22
Survivorship Program 23
Thoracic Oncology Program 24
Interdisciplinary Clinical Services:
Diagnostic Imaging, Body Imaging,
Breast Imaging And Nuclear Medicine 25
Interventional Radiology Services 26
Neuroradiology Services 27
Pathology Services 28
Interventional Pain Medicine Service 29
Cancer Prevention 30
Total Cancer Care™ – An Overview 31
Total Cancer Care™ Consortium 32
Medical Staff Index 33
Directions to Moffitt BACK COVER
4 Moffitt Medical Group
5. HOW TO REFER A PATIENT
TO M OFF IT T CANC E R CE N T E R
To refer a patient to a specific physician, program or service,
call the New Patient Appointment Center at 813-745-3980 or
1-888-860-2778, Mon-Fri, 8:00 am - 5:00 pm.
If you need assistance identifying the best physician for your patient
or have questions about Moffitt Cancer Center’s programs and services,
call our Physician Resource Line at 1-888-MOFFITT.
To determine if a Moffitt clinical trial is available for your patient,
call 813-745-4106 or visit www.MOFFITT.org.
To refer an international patient, please call our International Relations
Department at 813-745-3571 or 813-745-4216.
> Key Telephone Numbers
Moffitt Cancer Center............................................................. 813-745-4673
800-456-3434
Physician Resource Line........................................................888-MOFFITT
New Patient Appointment Center......................................... 813-745-3980
Mon-Fri, 8:00 am - 5:00 pm 888-860-2778
Lifetime Cancer Screening & Prevention Center............... 813-745-6769
Clinical Trials Office................................................................ 813-745-4106
Cancer Answers...................................................................... 800-456-7121
888-MOFFITT
Pharmacy. ............................................................................... 813-745-8485
.
Patient Relations.................................................................... 813-745-3808
International Relations............................................................ 813-745-3571
or 813-745-4216
Web Site............................................................................ www.MOFFITT.org
MOFFITT.org 5
6. M offitt Can cer Center Ad d s Lo ca ti o n
N ear Inter n at io n al P la za
The opening of Moffitt Cancer Center near
International Plaza and the Tampa International
Airport allows Moffitt to provide expanded services
that are easily accessible to more patients. Just
as at Moffitt’s main facility on the University of
South Florida campus, Moffitt’s outpatient center
located near International Plaza gives patients
the opportunity to participate in clinical trials and
translational research studies.
Hillsborough Ave.
Services at the International Plaza location include:
Dale Mabry Highway
Veterans Expressway
• oncology physician practice office visits for Tampa
International
Airport
medical, surgical and radiation oncology Raymond
James
Stadium
• infusion services (24 private chemotherapy Moffitt Cancer Center
at International Plaza
infusion bays) Jim Walter Blvd.
Columbus Dr.
International d.
Blv
• blood draw area and clinical laboratory Plaza
ut
Getting to
o
Sc
Spruce St. B oy
Westshore Blvd.
• radiation therapy
Moffitt Cancer
Lois Ave.
• radiology (PET, CT, MRI, chest x-ray and
Center’s Facility
mammography/ultrasound)
At International Kennedy Blvd.
Moffitt Cancer Center at International Plaza is Plaza
located at 4101 Jim Walter Blvd., Tampa, FL 33607.
Located in south Tampa, our satellite facility is adjacent to International
Phone: 813-745-1600
Plaza, on the east side of the Tampa International Airport property.
The operating hours are scheduled for 7:00 a.m. to
I-4 west, merge onto I-275 south towards St. Petersburg. Then
5:00 p.m., Monday through Friday, with the ability follow 1-275 directions.
to expand hours during weekdays and Saturdays in
I-75 south, merge onto I-275 south towards St. Petersburg. Then
the future. follow 1-275 directions.
I-275, traveling north or south, take exit 41B onto Dale Mabry
Physicians who also see patients at Moffitt Cancer Highway northbound and continue to Columbus Drive. Turn left onto
Center’s satellite location near International Plaza Columbus Drive and proceed west. Turn right at the first traffic light
are marked with an asterisk ([ ) in this directory. onto Jim Walter Boulevard. You will see the Center’s main entrance
immediately on your right.
Veterans Expressway traveling south, continue on to FL-60 east.
Take exit 1B for Spruce Street toward Raymond James Stadium. Merge
onto West Spruce Street and continue onto Boy Scout Boulevard. Turn
left onto Jim Walter Boulevard. You will see the Center’s main entrance
immediately on your right.
6 Moffitt Medical Group
8. B LOOD AN D MAR ROW T RA N S PL A N T PRO G RA M
D E PA R T M E N T C H A I R A N D
PROGRAM LEADER
Overview
Claudio Anasetti, MD
Medical Oncology The Blood and Marrow Transplant (BMT) Program
813-745-2557 opened at Moffitt Cancer Center in 1989. The Cancer
claudio.anasetti@moffitt.org Center’s BMT Program is now one of the largest in the
United States, performing more than 350 transplants a
year. More than 500 transplant-related admissions and
MEDICAL ONCOLOGISTS Lia E. Perez, MD over 13,000 clinic visits to BMT medical providers occur
A N D H E M AT O L O G I S T S Hematology annually. Moffitt’s BMT Program is accredited by FACT
Melissa Alsina, MD 813-745-2557 (Foundation for the Accreditation of Cellular Therapies).
Hematology lia.perez@moffitt.org
The BMT Program offers autologous, related and
Head, Multiple Myeloma Joseph Pidala, MD, MS unrelated allogeneic blood and marrow stem cell and
Transplant Program Medical Oncology
813-745-7202 umbilical cord blood transplantation for a variety
813-745-6012
melissa.alsina@moffitt.org of hematologic and oncologic disorders, including
joseph.pidala@moffitt.org
leukemia, lymphoma, multiple myeloma, myelodysplasia,
Claudio Anasetti, MD Daniel Sullivan, MD
Medical Oncology aplastic anemia and selected solid tumors. Data are
Medical Oncology
813-745-2557 Executive Vice President/
reported to the National Marrow Donor Program and
claudio.anasetti@moffitt.org Associate Center Director, the Center for International Bone Marrow Transplant
Ernesto Ayala, MD Clinical Investigations Research.
Medical Oncology, Hematology 813-745-3878 The BMT Program includes an interdisciplinary team
813-745-8248 dan.sullivan@moffitt.org
of BMT-trained physicians, physician assistants, nurse
ernesto.ayala@moffitt.org Marcie Tomblyn, MD, MS practitioners, nurses, pharmacists, social workers,
Brian C. Betts, MD Medical Oncology, Hematology dietitians, and laboratory personnel. An outpatient
Medical Oncology, Hematology 813-745-7202
center provides pre-transplant evaluation and post-
813-745-7202 marcie.tomblyn@moffitt.org
transplant follow-up care.
brian.betts@moffitt.org
William S. Dalton, PhD, MD OTHER SPECIALISTS Research
Medical Oncology
President/CEO and Center Director John N. Greene, MD Ongoing studies are directed at improving the
813-745-4261 Infectious Diseases efficacy of autologous stem cell transplantation,
william.dalton@moffitt.org 813-745-8408 decreasing morbidity by lowering the intensity of the
john.greene@moffitt.org
Hugo F. Fernandez, MD conditioning regimen before related and unrelated
Hematology transplantation,and improving the prevention and
813-745-6012 treatment of graft-versus-host disease.
hugo.fernandez@moffitt.org
Teresa L. Field, MD, PhD
Hematology
813-745-8248
teresa.field@moffitt.org
Frederick Locke, MD
Medical Oncology
813-745-8248
frederick.locke@moffitt.org
Taiga Nishihori, MD
Medical Oncology, Hematology
813-745-7202
taiga.nishihori@moffitt.org
José Leonel Ochoa-Bayona, MD
Medical Oncology, Hematology
813-745-7202
leonel.ochoa@moffitt.org
[ THESE PHYSICIANS ALSO SEE PATIENTS AT MOFFITT CANCER
CENTER’S SATELLITE LOCATION NEAR INTERNATIONAL PLAZA.
To refer patients for BMT: 813-745-8751 or 813-745-8530
To refer a patient: 813-745-3980 or 1-888-860-2778, Mon-Fri, 8:00 am - 5:00 pm
Information about clinical trials: 813-745-4106
8 Moffitt Medical Group
9. Th e Ce nte r For Wom e n’s O n co lo g y :
DON AND ERIKA WALLACE COMPREHENSIVE BREAST PROGRAM
DIRECTOR, THE CENTER FOR WOMEN’S ONCOLOGY
Johnathan M. Lancaster, MD, PhD, FACS, FACOG
Overview
Women’s Oncology and Gynecologic Oncology
813-745-6300 Moffitt’s Don and Erika Wallace Comprehensive Breast
johnathan.lancaster@moffitt.org Program offers a team approach for the prevention,
diagnosis and treatment of breast cancer in men and
women. As part of The Center for Women’s Oncology at
Moffitt, services are provided with an interdisciplinary
SURGEONS MEDICAL ONCOLOGISTS approach to deliver the most advanced care for patients
[ Nazanin Khakpour, MD, FACS Karen K. Fields, MD and their families.
Surgical Oncology Medical Oncology/Hematology
813-745-6300 813-745-6300 Our breast surgeons are leaders in breast-conserving
nazanin.khakpour@moffitt.org karen.fields@moffitt.org surgery, nipple-sparing/skin-sparing mastectomy and
sentinel lymph node mapping techniques which often
John V. Kiluk, MD, FACS Hyo (Heather) S. Han, MD
Surgical Oncology Medical Oncology/Hematology result in less invasive axillary surgery. Other therapies
813-745-6300 813-745-6300 include breast-conservation therapy with intraoperative
john.kiluk@moffitt.org hyo.han@moffitt.org breast irradiation (IORT), adjuvant or hormonal therapy
Christine Laronga, MD, FACS Roohi R. Ismail-Khan, MD and the most current chemotherapy regimens. The
Surgical Oncology Medical Oncology latest techniques in plastic and reconstructive surgery
Clinical Director, Breast 813-745-6300 are also available.
Surgical Oncology roohi.ismail-khan@moffitt.org Radiology services include screening mammography,
813-745-6300
christine.laronga@moffitt.org
[ Loretta S. Loftus, MD, MBA, FACP CAD (computer-aided detection), digital mammography,
Medical Oncology/Hematology breast ultrasound, breast MRI and minimally invasive
[ M. Catherine Lee, MD, FACS 813-745-6300
core biopsy (ultrasound-guided stereotactic and MRI-
Surgical Oncology loretta.loftus@moffitt.org
813-745-6300 guided).
marie.lee@moffitt.org
[ Susan E. Minton, DO
Medical Oncology Research
813-745-6300
susan.minton@moffitt.org The Don and Erika Wallace Comprehensive Breast
PLASTIC AND RECONSTRUCTIVE
SURGEONS Hatem Soliman, MD Program can offer a wide range of clinical trials to
Medical Oncology/Hematology patients, including investigator-initiated studies,
Deniz Dayicioglu, MD trials from national cooperative groups and select
Plastic and Reconstructive Surgery 813-745-6300
813-745-6300 hatem.soliman@moffitt.org pharmaceutical studies. The program currently has
deniz.dayicioglu@moffitt.org studies to evaluate neoadjuvant chemotherapy, surgical
treatment options, treatment of metastatic disease and
Anh H. Nguyen, MD
Plastic and Reconstructive Surgery new breast imaging modalities. Additional investigations
813-745-6300 focus on new risk markers and genetic screening. To
anh.nguyen2@moffitt.org refer a patient for possible participation in a clinical
Paul D. Smith, MD research study, contact the program at 813-745-1807.
Plastic and Reconstructive Surgery
813-745-6300
paulsmith@drpaulsmith.com
Karen E. Wells, MD, FACS
Plastic and Reconstructive Surgery
813-745-6300
karen.wells@moffitt.org
[ THESE PHYSICIANS ALSO SEE PATIENTS AT MOFFITT CANCER
CENTER’S SATELLITE LOCATION NEAR INTERNATIONAL PLAZA.
To refer a patient: 813-745-3980 or 1-888-860-2778, Mon-Fri, 8:00 am - 5:00 pm
Information about clinical trials: 813-745-4106
MOFFITT.org 9
10. CU TANEO U S O NCO LO GY PRO G RA M
D E PA R T M E N T C H A I R A N D
PROGRAM LEADER
Vernon K. Sondak, MD Overview
Surgical Oncology At Moffitt Cancer Center, we believe that cancer treatment is most
813-745-8788 effective when delivered by an integrated team of medical professionals
vernon.sondak@moffitt.org who specialize in site-specific cancers. The Cutaneous Oncology
Program, one of more than a dozen cancer treatment programs at
the Cancer Center, specializes in the evaluation and treatment of
SURGEONS D E R M AT O L O G I S T S patients with the most common skin cancers – basal and squamous
Ricardo J. Gonzalez, MD Basil S. Cherpelis, MD cell carcinoma – as well as melanoma, Merkel cell cancers and other
Surgical Oncology Dermatology/Mohs rare skin tumors. A multidisciplinary team of specialists provides a
813-745-6161 Micrographic comprehensive program of care for patients with all types of skin
ricardo.gonzalez@moffitt.org Surgery cancer, especially melanoma – the most serious type. Screening,
Amod A. Sarnaik, MD 813-974-4270 diagnosis, staging and treatment are provided, as well as long-term
Surgical Oncology bcherpel@health.usf.edu follow-up. The program’s comprehensive care includes the latest in
813-745-8581 Neil A. Fenske, MD investigational treatments and research for melanoma.
amod.sarnaik@moffitt.org Dermatology
813-974-4270 Florida has one of the highest rates of malignant melanoma and skin
Vernon K. Sondak, MD cancer in the nation due to its southern location and high levels of
Surgical Oncology nfenske@health.usf.edu
ultraviolet radiation exposure, and also because its population includes
813-745-8788 L. Frank Glass, MD
vernon.sondak@moffitt.org Dermatology/
older individuals with a lifetime of sun exposure. Roughly 5,000 new
Dermatopathology cases of melanoma will be diagnosed in Florida; this figure accounts for
Jonathan S. Zager, MD seven percent of the incidence rate for the entire country. Progress in
Surgical Oncology 813-974-3744
fglass@health.usf.edu early detection and treatment has improved the cure rate of melanoma,
813-745-1085
jonathan.zager@moffitt.org Mary H. Lien, MD but because curability depends greatly on the thickness of the skin
Dermatology tumor at diagnosis, early detection and aggressive surgical treatment
813-974-2188 are crucial.
PLASTIC SURGEONS
mlien@health.usf.edu The Cutaneous Oncology Program at Moffitt Cancer Center offers the
[ C. Wayne Cruse, MD most current diagnostic procedures available, including lymphatic
Plastic Surgery
813-844-8546 mapping and sentinel lymph node biopsy. All physicians in the
wcruse@health.usf.edu Cutaneous Oncology Program collaborate in the evaluation and
discussion of diagnostic test results and meet regularly to develop
Gerard C. Mosiello, MD
Plastic and Reconstructive Surgery therapeutic plans. The initial surgical biopsy results are confirmed
813-631-1500 by a dermatopathologist. Further evaluations may include computed
jerry@tampapalmsplasticsurgery.com tomography (CT) scans and positron emission tomography (PET) scans,
magnetic resonance imaging (MRI), and ultrasound of lymph node areas
MEDICAL ONCOLOGISTS
at risk for metastasis. Fine needle aspiration biopsies of regional lymph
nodes and sites of possible metastasis may be used, if necessary.
Ronald C. DeConti, MD Ragi R. Kudchadkar, MD
Medical Oncology Medical Oncology With the incidence of skin cancer increasing in the state of Florida,
813-745-8788 813-745-8581 Moffitt Cancer Center established the Mole Patrol™, which provides free
ronald.deconti@moffitt.org ragini.kudchadkar@moffitt.org skin cancer screening to Florida residents in partnership with Moffitt
Geoffrey Gibney, MD Jeffrey S. Weber, MD, PhD affiliates around the state. The Mole Patrol helps to raise awareness
Medical Oncology Medical Oncology/Immunology of the importance of early detection and prevention of skin cancer.
813-745-8482 Director, Donald A. Adam The Mole Patrol™ is often present at Florida’s beaches and public
geoffrey.gibney@moffitt.org Comprehensive Melanoma events, including air shows and sporting events, offering a variety of
David E. Jones, Jr, MD, PhD Research Center educational materials about sun safety to the public.
Medical Oncology 813-745-2007
813-745-8482 jeffrey.weber@moffitt.org Research
david.jones@moffitt.org The Cutaneous Oncology Program participates in clinical trials
supported by Moffitt, the National Institutes of Health, cooperative
groups and selected pharmaceutical companies. Since its inception
in 1987, members of the Cutaneous Oncology Program have had an
interest in immunotherapeutic approaches to the disease. A number of
chemotherapy and immunotherapy protocols and even gene transfer
studies are underway for patients with metastatic melanoma. Program
members are collaborating with basic science researchers to increase
[ THESE PHYSICIANS ALSO SEE PATIENTS AT MOFFITT our understanding of the biology and epidemiology of skin cancers and
CANCER CENTER’S SATELLITE LOCATION NEAR devise new treatment approaches based on this knowledge.
INTERNATIONAL PLAZA.
To refer a patient with melanoma and nonmelanoma skin cancer: 813-745-1968
Information about clinical trials: 813-745-4106
10 Moffitt Medical Group
11. EN DOC RIN E T U MO R P RO G RA M
PROGRAM LEADER
W. Bradford Carter, MD, FACS, FACE Overview
Surgical Oncology/Endocrine Surgery
813-745-1965 The Endocrine Tumor Program provides a full range of
bradford.carter@moffitt.org services for all endocrine disorders. Moffitt physicians
have extensive expertise in diagnosing and treating all
endocrine disorders, both cancerous and benign. This
clinic provides comprehensive evaluation and treatment
E N D O C R I N E S U G E RY planning of all endocrine disorders, including tumors of
W. Bradford Carter, MD, FACS, FACE the thyroid, parathyroid, pituitary and adrenal, as well
Surgical Oncology/Endocrine Surgery as endocrine effects of cancer, including osteoporosis.
813-745-1965 We provide advanced treatment techniques in endocrine
bradford.carter@moffitt.org surgery, such as laparoscopic adrenalectomy, minimally
invasive and radio-guided parathyroidectomy, minimally
invasive thyroidectomy, laparoscopic surgery for
ENDOCRINOLOGISTS
islet cell tumor of the pancreas and microsurgery
Howard S. Lilienfeld, MD, FACP, FACE for pituitary tumors. We also provide world-class
Endocrinologist specializing in pituitary, adrenal and thyroid disorders
expertise in neuroendocrine tumors, multiple endocrine
Section Chief, Endocrinology
813-745-1965 neoplasias and other genetic endocrinopathies. Genetic
howard.lilienfeld@moffitt.org counseling and testing are part of the diagnostic and
treatment options available for these patients. While
John B. Tourtelot, MD, FACP, FACE
cancers of the endocrine glands are rare, the treatment
Endocrinology
813-745-1965 requires special diagnostics and treatment.
john.tourtelot@moffitt.org The Endocrine Tumor Program has expanded its surgery
services to include da Vinci® Surgical System robotic-
assisted surgery for the removal of adrenal tumors,
including pheochromocytomas. Robotic-assisted thyroid
surgery also is offered, and the procedure is performed
through a transaxillary approach that does not require
any neck incisions.
Research
Clinical and basic science research within the program
is searching to advance treatment of thyroid and
adrenocortical cancer and to define cancer interactions
with endothelial cells and vascular tissues.
[ THESE PHYSICIANS ALSO SEE PATIENTS AT MOFFITT CANCER
CENTER’S SATELLITE LOCATION NEAR INTERNATIONAL PLAZA.
To refer a patient: 813-745-3980 or 1-888-860-2778, Mon-Fri, 8:00 am - 5:00 pm
Information about clinical trials: 813-745-4106
MOFFITT.org 11
12. GASTROINT EST INAL O N CO LO GY PRO G RA M
D E PA R T M E N T C H A I R A N D
PROGRAM LEADER
Overview
[ Mokenge P. Malafa, MD, FACS
Surgical Oncology The Gastrointestinal (GI) Oncology Program is a
Head, Section of Hepatopancreatobiliary Oncology specialized interdisciplinary program that focuses on
813-745-1432 the treatment and prevention of cancers of the GI tract,
mokenge.malafa@moffitt.org including colorectal, esophageal, liver, and pancreatic
cancer. Our interdisciplinary team approach to patient
SURGEONS MEDICAL ONCOLOGISTS
care means that patients are seen by cancer specialists
Sophie Dessureault, MD, PhD, FACS, Khaldoun Almhanna, MD, MPH with expertise in GI oncology.
FRCS(C) Medical Oncology
Surgical Oncology 813-745-7257
khaldoun.almhanna@moffitt.org Research
Clerkship Director
813-745-3636 Lodovico Balducci, MD Currently, Moffitt Cancer Center is aggressively
sophie.dessureault@moffitt.org Medical Oncology/Hematology developing new drugs to treat patients with cancers of
Pamela J. Hodul, MD Program Leader, Senior Adult Oncology the GI system. A mission of the GI Oncology Program
Surgical Oncology 813-745-8658 is to develop new treatments for diseases of the GI
813-745-1277 lodovico.balducci@moffitt.org tract. For many years, only a few select treatments
pamela.hodul@moffitt.org William R. Dinwoodie, MD and drugs were available to treat GI tumors. In pursuit
Richard C. Karl, MD, FACS Medical Oncology of the program’s mission, the GI team has developed
Surgical Oncology 813-745-3636
william.dinwoodie@moffitt.org alliances with the National Cancer Institute’s Cancer
813-745-1277 Therapy Evaluation Program (CTEP), multi-institutional
richard.karl@moffitt.org Martine Extermann, MD, PhD
cooperative groups including the Southwest Oncology
Medical Oncology
[ Mokenge P. Malafa, MD, FACS Group (SWOG), the Moffitt Drug Discovery Program, and
813-745-3822
Surgical Oncology select pharmaceutical companies. The team focuses on
martine.extermann@moffitt.org
Head, Section of Hepatopancreatobiliary
selecting drugs that have the ability to target tumor
Oncology [ Jennifer L. Giglia, MD
813-745-1432 Medical Oncology cells with greater precision than standard drugs can.
mokenge.malafa@moffitt.org 813-745-1622 Members of the GI Oncology Program strongly believe
jennifer.giglia@moffitt.org this aggressive approach to finding new treatments will
[ Kenneth L. Meredith, MD, FACS contribute to the prevention and cure of cancers of the
Surgical Oncology Richard Kim, MD
Head, Section of Esophagogastric Medical Oncology GI system.
Oncology 813-745-1277
richard.kim@moffitt.org The GI Oncology Program has numerous open clinical
813-745-6898 trials, including phase I trials that give patients the
kenneth.meredith@moffitt.org Larry K. Kvols, MD
Medical Oncology opportunity to be treated with the newest drugs that
David Shibata, MD, FACS show promise in the laboratory. In addition, physicians
813-745-7257
Surgical Oncology and scientists at Moffitt conduct basic science and
larry.kvols@moffitt.org
Head, Section of Colorectal Oncology
813-745-6898 Gregory M. Springett, MD, PhD clinical research related to GI cancers. The goal of
david.shibata@moffitt.org Medical Oncology this translational research is to bring new knowledge
813-745-6898 and treatments to the patient as quickly as possible.
Timothy J. Yeatman, MD, FACS gregory.springett@moffitt.org
Surgical Oncology In addition to its own research programs, Moffitt also
Executive Vice President & Founding Jonathan R. Strosberg, MD participates in numerous regional and national cancer
Chief Scientific Officer, M2Gen Medical Oncology studies.
813-745-7292 Head, Section of Neuroendocrine
timothy.yeatman@moffitt.org Oncology
813-745-7257
jonathan.strosberg@moffitt.org
E N D OS CO P I C O N CO LO GY
James S. Barthel, MD, FACP, Cynthia L. Harris, MD Jason B. Klapman, MD
FACG, FASGE Gastroenterology Gastroenterology
Gastroenterology 813-745-8361 813-745-8361
Head, Section of Endoscopic Oncology cynthia.harris@moffitt.org jason.klapman@moffitt.org
813-745-8361 James F. Helm, MD, PhD Shivakumar Vignesh, MD
james.barthel@moffitt.org Gastroenterology Gastroenterology
813-745-8361 813-745-8361
james.helm@moffitt.org shivakumar.vignesh@moffitt.org
[ THESE PHYSICIANS ALSO SEE PATIENTS AT MOFFITT CANCER CENTER’S SATELLITE LOCATION NEAR INTERNATIONAL PLAZA.
To refer a patient: 813-745-3980 or 1-888-860-2778, Mon-Fri, 8:00 am - 5:00 pm
Information about clinical trials: 813-745-4106
12 Moffitt Medical Group
13. G ENITOUR INA RY O NCO LO GY PRO G RA M
D E PA RT M E N T C H A I R A N D
PROGRAM LEADER
Overview
[ Julio M. Pow-Sang, MD
Urologic Surgery The Genitourinary Oncology Program provides a highly
813-745-8418 specialized team of physicians from multiple fields of
julio.powsang@moffitt.org cancer medicine whose expertise is treating patients
with genitourinary malignancies. These include cancers
of the male and female urinary systems (prostate,
SURGEONS testicles, penis, kidneys, ureters and bladder). The goals
Jorge L. Lockhart, MD of the practice are to provide state-of-the-art care and
Urologic Surgery develop more effective therapies for patients.
813-259-8702 Some urologic cancers, such as testicular cancer, now
jorge.lockhart@moffitt.org are treated successfully with chemotherapy. Others,
[ Julio M. Pow-Sang, MD such as bladder cancer, are showing better response to
Urologic Surgery new combinations of chemotherapy. New treatments for
813-745-8418
kidney cancer include biological therapy, which uses the
julio.powsang@moffitt.org
body’s own immune system to fight cancer.
Wade J. Sexton, MD
Urologic Surgery Several standard and new therapies are being studied
813-745-8418 for their ability to lower the prostate-specific antigen
wade.sexton@moffitt.org (PSA) and inhibit the spread of disease to the bone
Philippe E. Spiess, MD and other distant sites. Men whose PSA is rising after
Urologic Surgery prostatectomy, radioactive seed therapy, external
813-745-8418 radiation, or testosterone deprivation with leuprolide,
philippe.spiess@moffitt.org goserelin, or orchiectomy are candidates for the
Genitourinary Medical Oncology clinic where dedicated
MEDICAL ONCOLOGISTS
specialists are studying new treatments for prostate
cancer.
Mayer N. Fishman, MD, PhD
Medical Oncology An additional focus of the program is to respond to
813-745-8418 the needs of patients of advanced age with advanced
mayer.fishman@moffitt.org prostate cancer. The needs and desires of older patients
[ Shilpa Gupta, MBBS (MD) can differ from those of younger patients. For example,
Medical Oncology younger patients often choose the most effective
813-745-8418 available therapies and place little emphasis on potential
shilpa.gupta@moffitt.org side effects. The Genitourinary Oncology Program works
Julie A. Kish, MD, FACP closely with the Senior Adult Oncology Program to
Medical Oncology provide care and develop treatments for older patients.
813-745-3822
julie.kish@moffitt.org Moffitt urologic surgeons use the da Vinci® Surgical
System to perform robotic-assisted surgery for patients
Jingsong Zhang, MD
Medical Oncology with prostate, kidney and bladder cancers. Dr. Pow-Sang
813-745-8418 has experience using robotic-assisted surgery to perform
jingsong.zhang@moffitt.org retroperitoneal lymph node dissection to remove
abdominal lymph nodes in treating testicular cancer.
Research
Physicians in the Genitourinary Oncology Program
are actively involved in national and Moffitt-generated
clinical studies, as well as laboratory research projects
that may yield the new urologic cancer treatments of
tomorrow. When appropriate, patients can participate in
clinical studies that seek to take a standard treatment
and improve its tolerability or efficacy. These studies use
the newest and most promising cancer treatments and
drugs.
[ THESE PHYSICIANS ALSO SEE PATIENTS AT MOFFITT CANCER
CENTER’S SATELLITE LOCATION NEAR INTERNATIONAL PLAZA.
To refer a patient: 813-745-3980 or 1-888-860-2778, Mon-Fri, 8:00 am - 5:00 pm
Information about clinical trials: 813-745-4106
MOFFITT.org 13
14. Th e Ce nte r For Wom e n’s O n co lo g y :
GY NECO LOGIC ONCOLOGY P RO GRA M
D E PA RT M E N T C H A I R
PROGRAM LEADER
DIRECTOR, THE CENTER FOR Overview
WOMEN’S ONCOLOGY The Gynecologic Oncology Program specializes in
Johnathan M. Lancaster, MD, PhD, FACS, FACOG the treatment and evaluation of women with ovarian,
Women’s Oncology and Gynecologic Oncology cervical, endometrial, vulvar, or vaginal cancers or
813-745-6300 gestational trophoblastic disease.
johnathan.lancaster@moffitt.org
Research
GY N ECO LO G I C O N CO LO G I STS
Clinicians and basic researchers regularly collaborate
Sachin M. Apte, MD to discover more effective therapies for gynecologic
Gynecologic Oncology cancers. The program has active translational and
813-745-6300 clinical research protocols, including the application of
sachin.apte@moffitt.org
genomics to develop personalized therapy for ovarian
[ Jesus Gonzalez Bosquet, MD, PhD, FACOG cancer. The program enrolls patients in active phase I,
Gynecologic Oncology II and III clinical trials for gynecologic malignancies. In
813-745-6300 addition to its own research programs, Moffitt Cancer
jesus.gonzalezbosquet@moffitt.org Center participates in many regional and national
[ Patricia L. Judson, MD cancer treatment studies, including those offered by the
Gynecologic Oncology Gynecologic Oncology Group (GOG). The Gynecologic
813-745-6300 Oncology Program at Moffitt is the site of the principal
patricia.judson@moffitt.org investigative body of the Tampa Bay Cancer Consortium,
Johnathan M. Lancaster, MD, PhD, FACS, FACOG an organization of hospitals and universities involved in
Gynecologic Oncology GOG research.
813-745-6300
johnathan.lancaster@moffitt.org
William S. Roberts, MD, FACS, FACOG
Gynecologic Oncology
813-745-6300
william.roberts@moffitt.org
Robert M. Wenham, MD, FACS, FACOG
Gynecologic Oncology
813-745-6300
robert.wenham@moffitt.org
[ THESE PHYSICIANS ALSO SEE PATIENTS AT MOFFITT CANCER
CENTER’S SATELLITE LOCATION NEAR INTERNATIONAL PLAZA.
To refer a patient: 813-745-3980 or 1-888-860-2778, Mon-Fri, 8:00 am - 5:00 pm
Information about clinical trials: 813-745-4106
14 Moffitt Medical Group
15. H EA D AND NEC K O NCO LO GY PRO G RA M
PROGRAM LEADER
Thomas V. McCaffrey, MD, PhD Overview
Otolaryngology
813-745-3057 The Head and Neck Oncology Program provides
thomas.mccaffrey@moffitt.org comprehensive, patient-oriented care for all types and
stages of head and neck cancer and thyroid cancer,
with special attention to preservation, quality of life,
rehabilitation and education. Physicians and staff are
S U R G I C A L O N C O L O G Y/ S K U L L B A S E M A X I L L O FA C I A L dedicated to providing the newest and most effective
S U R G E R Y/ T H Y R O I D D I S O R D E R S PROSTHETICS care to patients while striving to blend compassion and
Kathryn L. Hall, MD Terry M. Kelly, DMD, PA technique in their care approach.
Otolaryngology Reconstructive & Implant Services include all phases of care ranging from
813-250-2216 Prosthodontics
diagnosis and treatment to reconstruction and
khall@health.usf.edu 813-971-0620
terry.kelly@verizon.net rehabilitation. With a focus on preservation and
Judith C. McCaffrey, MD rehabilitation, the program offers plastic and
Otolaryngology
reconstructive surgery, microvascular free-tissue
813-745-8363
judith.mccaffrey@moffitt.org
OTO L A RY N G O LO G I STS transfer, maxillofacial prosthodontics, extensive
Alec Beningfield, MD speech and swallowing rehabilitation and psychosocial
Thomas V. McCaffrey, MD, PhD Otolaryngology
Otolaryngology
consultation. Expertise in the diagnosis and treatment
813-974-6573 of complex skull base tumors is provided through
813-745-3057
abeningf@health.usf.edu the Center for Skull Base Oncology at Moffitt, an
thomas.mccaffrey@moffitt.org
Marion B. Ridley, MD interdisciplinary effort between the Neuro-Oncology and
Tapan A. Padhya, MD Otolaryngology
Otolaryngology Head and Neck Oncology Programs.
813-974-4706
813-745-8363
mridley@health.usf.edu Research
tapan.padhya@moffitt.org
Mark H. Tabor, MD
Frank D. Vrionis, MD, MPH, PhD Clinicians and basic scientists work together to discover
Otolaryngology
Neurological Surgery new treatments and cures for head and neck cancers.
813-250-2216
Chief of Neurosurgery This translational approach to research brings together
mtabor@health.usf.edu
813-745-4251 the best in research from both clinical and laboratory
frank.vrionis@moffitt.org
perspectives. Members of the Head and Neck Oncology
HEAD AND NECK MEDICAL Program participate in national, regional and industry-
ONCOLOGISTS
O T O L O G Y/ N E U R O T O L O G Y/ based clinical trials. Current trials include:
L AT E R A L S K U L L B A S E Ronald C. DeConti, MD
S U RG E RY Medical Oncology • Phase II and phase III trials for advanced
813-745-8466 metastatic or recurrent cancers of the head and
K. Paul Boyev, MD neck of squamous cell origin
ronald.deconti@moffitt.org
Otolaryngology
813-974-6573 Julie A. Kish, MD, FACP • The latest chemotherapy trials including
pboyev@health.usf.edu Medical Oncology tamoxifen and docetaxel
813-745-3822
julie.kish@moffitt.org
HEAD AND NECK
Tawee Tanvetyanon, MD
M I C R O VA S C U L A R
Medical Oncology
RECONSTRUCTION
813-745-8477
Mark El-Deiry, MD tawee.tanvetyanon@moffitt.org
Otolaryngology
813-745-8363
mark.eldeiry@moffitt.org
[ THESE PHYSICIANS ALSO SEE PATIENTS AT MOFFITT CANCER
CENTER’S SATELLITE LOCATION NEAR INTERNATIONAL PLAZA.
To refer a patient: 813-745-3980 or 1-888-860-2778, Mon-Fri, 8:00 am - 5:00 pm
Information about clinical trials: 813-745-4106
MOFFITT.org 15
16. IN TE RNAL A ND HOS P I TA L M E D I CI N E PRO G RA M
PROGRAM LEADER
Debra L. Anoff, MD, FACP Overview
Internal and Hospital Medicine
813-745-3134 The Internal and Hospital Medicine (IHM) Program
debra.anoff@moffitt.org focuses on medical conditions that interact with a
patient’s cancer management. We manage other
diseases that may be present during care at Moffitt,
such as diabetes, heart and lung problems, infections
INTERNISTS and other complications. In addition, program
Debra L. Anoff, MD, FACP physicians provide care to hospitalized patients, work
Internal and Hospital Medicine with surgeons to identify and reduce surgical risk and
813-745-3134 coordinate care with subspecialists. Functioning largely
debra.anoff@moffitt.org as hospitalists, the IHM physicians also oversee Moffitt’s
Susmitha Apuri, MD Direct Referral Center for urgent problems and maintain
Internal and Hospital Medicine active clinics for follow-up on inpatients, high-risk
813-745-4119 preoperative patients and a variety of other noncancer
susmitha.apuri@moffitt.org patient needs including anticoagulation management.
Bryan A. Bognar, MD, MPH, FACP
Internal and Hospital Medicine Research
813-745-3134
bryan.bognar@moffitt.org Physicians in the IHM Program play major administrative
and teaching roles with students and residents at the
Kristin Carlin, DO
Internal and Hospital Medicine University of South Florida College of Medicine. They
813-745-3134 have contributed to national medical textbooks, have
kristin.carlin@moffitt.org published in a number of different areas, and are
Lucy Guerra, MD, MPH, FACP recognized as leaders in medical education.
Internal and Hospital Medicine
813-745-3134
lucy.guerra@moffitt.org
Ebone’ Hill, MD
Internal and Hospital Medicine
813-745-4119
ebone.hill@moffitt.org
Bjorn Holmstrom, MD
Internal and Hospital Medicine
813-745-3134
bjorn.holmstrom@moffitt.org
Smitha Pabbathi, MD
Internal and Hospital Medicine
813-745-4119
smitha.pabbathi@moffitt.org
Carlos Palacio, MD
Internal and Hospital Medicine
813-745-4119
carlos.palacio@moffitt.org
[ THESE PHYSICIANS ALSO SEE PATIENTS AT MOFFITT CANCER
CENTER’S SATELLITE LOCATION NEAR INTERNATIONAL PLAZA.
To refer a patient: 813-745-3980 or 1-888-860-2778, Mon-Fri, 8:00 am - 5:00 pm
Information about clinical trials: 813-745-4106
16 Moffitt Medical Group
17. M A L IGNA NT HE MATO LO GY PRO G RA M
D E PA RT M E N T C H A I R A N D
PROGRAM LEADER
Overview
Eduardo M. Sotomayor, MD
Medical Oncology The Malignant Hematology Program specializes in
813-745-1387 the evaluation, treatment, and comprehensive care of
eduardo.sotomayor@moffitt.org patients with lymphoma, leukemia, multiple myeloma,
myelodysplastic syndrome, and myeloproliferative
syndrome. The program is recognized as a Center of
MEDICAL ONCOLOGISTS AND Jeffrey E. Lancet, MD Excellence by the Myelodysplasia (MDS) Foundation
H E M AT O L O G I S T S Hematology, Medical Oncology and is one of four founding institutions of the Bone
Melissa Alsina, MD Section Head, Leukemia/ Marrow Failure (BMF) Consortium funded by the
Hematology Myelodysplasia National Institutes of Health. All patients with MDS,
813-745-7202 813-745-6841
jeffrey.lancet@moffitt.org large granular lymphocytic leukemia, aplastic anemia or
melissa.alsina@moffitt.org
other rare causes of bone marrow failure are registered
Lodovico Balducci, MD Alan F. List, MD in the Consortium’s national database, which was
Hematology, Medical Oncology Hematology, Medical Oncology
Executive Vice President, developed and is maintained at Moffitt Cancer Center.
Program Leader, Senior Adult Oncology
813-745-8658 Clinical Sciences The BMF Consortium is the first and only cooperative
lodovico.balducci@moffitt.org Physician-In-Chief network developed by the National Institutes of Health
President, Moffitt Medical Group for the study of the biology and development of novel
Rachid Baz, MD 813-745-6086
Hematology, Medical Oncology therapeutics for these disorders.
alan.list@moffitt.org
Section Head, Myeloma Although chemotherapy remains an integral
813-745-8212 Javier Pinilla-Ibarz, MD, PhD component of the treatment for most hematologic
rachid.baz@moffitt.org Hematology, Medical Oncology
813-745-1387
malignancies, the development of disease-specific
Celeste Bello, MD javier.pinilla@moffitt.org or targeted therapeutics represents the research
Hematology, Medical Oncology goal of Moffitt investigators who treat patients with
813-745-4294 Hussain I. Saba, MD, PhD
Hematology lymphoma, leukemias, and multiple myeloma. Marrow
celeste.bello@moffitt.org
813-972-7582 or stem cell transplantation often is indicated for the
[ Salvador Bruno, MD hussain.saba@moffitt.org treatment of hematologic malignancies. The treatment
Medical Oncology
Bijal Shah, MD protocols of the Malignant Hematology Program
813-745-1622
salvador.bruno@moffitt.org Medical Oncology, Hematology are integrated with those of the Blood and Marrow
813-745-8212 Transplantation Program. The Cancer Center has state-
[ Paul A. Chervenick, MD bijal.shah@moffitt.org of-the-art facilities for both inpatient and outpatient
Hematology
Medical Director, Moffitt Cancer Center Kenneth Shain, MD, PhD administration of chemotherapy.
at International Plaza Medical Oncology
813-745-1622 813-745-6841 Research
paul.chervenick@moffitt.org ken.shain@moffitt.org Research is ongoing in basic research laboratories,
Jennifer Cultrera, MD Lubomir Sokol, MD, PhD where scientists are investigating how the diseases
Medical Oncology Hematology, Medical Oncology originate, and in clinical investigations, where phase
813-745-4294 Section Head, Lymphoma
I and phase II studies are developed to introduce new
jennifer.cultrera@moffitt.org 813-745-8212
lubomir.sokol@moffitt.org drug therapies that can directly impact patient care.
William S. Dalton, PhD, MD The program emphasizes translational studies in which
Medical Oncology Eduardo M. Sotomayor, MD
the trials are designed by Moffitt investigators based on
President/CEO and Center Director Medical Oncology
813-745-1387 their preclinical findings. Moffitt investigators have led
813-745-4261
william.dalton@moffitt.org eduardo.sotomayor@moffitt.org the development of several promising new molecules
that may alter the management of patients with these
Martine Extermann, MD, PhD Kenneth S. Zuckerman, MD
Hematology diseases.
Medical Oncology
Senior Adult Oncology Program 813-745-8090
813-745-3822 ken.zuckerman@moffitt.org
martine.extermann@moffitt.org
Rami S. Komrokji, MD
Hematology, Medical Oncology
Clinical Director
813-745-4294
rami.komrokji@moffitt.org
[ THESE PHYSICIANS ALSO SEE PATIENTS AT MOFFITT CANCER
CENTER’S SATELLITE LOCATION NEAR INTERNATIONAL PLAZA.
To refer a patient: 813-745-3980 or 1-888-860-2778, Mon-Fri, 8:00 am - 5:00 pm
Information about clinical trials: 813-745-4106
MOFFITT.org 17
18. N EURO-O NCO LO GY P RO G RA M
D E PA RT M E N T C H A I R A N D
PROGRAM LEADER
Overview
[ Peter A. Forsyth, MA, MD
Neuro-Oncology The Neurosurgery and Neuro-Oncology Department is committed
813-745-3200 to providing the best possible care for complex tumors of the brain
peter.forsyth@moffitt.org and spine. Moffitt is committed to creating new standards to provide
optimal outcomes to our patients with tumors of the central nervous
system, including primary (glioma) and secondary (metastatic) cancer,
NEUROLOGICAL SURGEONS as well as benign tumors of the skull base (pituitary tumors, acoustic
Surbhi Jain, MD neuromas, meningiomas). Advanced neuroimaging, including fiber
Neurological Surgery tracking and motor mapping, defines the eloquent areas of the brain
813-745-3200 and provides optimal surgical outcomes. Patients receive intensive,
surbhi.jain@moffitt.org personalized care and are followed with our referring physicians for
Donald A. Smith, MD lifetime surveillance. Tumors formerly considered inoperable can be
Neurological Surgery safely removed using minimally invasive techniques.
813-259-0633
Surgery is complemented by the Novalis stereotactic radiosurgery unit
dosmith52@yahoo.com
for metastatic cancer and for skull base tumors. The Neuro-Oncology
Nam D. Tran, MD, PhD Program is recognized by the National Cancer Institute (NCI) as a
Neurological Surgery
founding and active member of the Adult Brain Tumor Consortium
813-745-3200
nam.tran@moffitt.org (ABTC, formerly NABTT), the only ABTC center in Florida that has a
continual offering of new protocols from the NCI. Moffitt is a pioneer
Frank D. Vrionis, MD, MPH, PhD
in the integration of biological, molecular-targeted therapy, including
Neurological Surgery
Chief of Neurosurgery antiangiogenic molecules such as bevacizumab (Avastin), cilengitide,
813-745-3200 sunitinib (Sutent), cediranib (Recentin), sorafenib (Nexavar), HDAC
frank.vrionis@moffitt.org inhibitors, vorinostat (Zolinza) and PARP inhibitors. We also are
evaluating the use of chemotherapeutic wafers to obtain control of
local tumors. For patients with glioblastoma, the dendritic cell vaccine
NEURO-ONCOLOGISTS
has shown promise. In concert with Moffitt Total Cancer Care™, we are
[ Peter A. Forsyth, MA, MD committed to provide the most comprehensive, customized care for our
Neuro-Oncology patients.
813-745-3200
peter.forsyth@moffitt.org For patients with spine tumors, Moffitt offers spinal stabilization to
[ Edward Pan, MD preserve neural function and improve quality of life. We emphasize
Neuro-Oncology minimally invasive techniques, such as retropleural thoracotomies,
813-745-3200 short segment fusions and the use of cages, to enhance fusion.
edward.pan@moffitt.org Procedures such as kyphoplasty and vertebroplasty are available to
reconstruct compressed vertebral bone, restore alignment or remove
pressure on a nerve.
NEUROLOGISTS
Edward Bass, MD Research
Neurology
813-745-3200 The Neuro-Oncology Program is built on strong clinical and basic
edward.bass@moffitt.org science research programs, uniting scientists in the fields of
neurosciences, molecular genetics, developmental neurobiology, cancer
biology, bioinformatics and epidemiology to understand how and why
OTHER SPECIALISTS
tumors develop in the central nervous system, as well as to uncover the
Howard S. Lilienfeld, MD, FACP, FACE mechanisms that result in tumor growth and resistance to therapy. The
Endocrinologist specializing in pituitary, Brain Tumor Research Laboratory focuses on antiangiogenesis and the
adrenal and thyroid disorders
development of other novel forms of adjuvant therapy for malignant
813-745-7257
howard.lilienfeld@moffitt.org brain tumors. Collaborative research includes investigation of the root
causes of brain tumor invasive spread and antiangiogenesis while
developing the next generation of safe, effective drugs to be integrated
with surgery, radiation therapy and chemotherapy.
[ THESE PHYSICIANS ALSO SEE PATIENTS AT MOFFITT CANCER
CENTER’S SATELLITE LOCATION NEAR INTERNATIONAL PLAZA.
To refer a patient: 813-745-3980 or 1-888-860-2778, Mon-Fri, 8:00 am - 5:00 pm
Information about clinical trials: 813-745-4106
18 Moffitt Medical Group
19. PSYC HOSO C IAL A ND PA L L I AT I V E CA RE PRO G RAM
PROGRAM LEADER
Bryan A. Bognar, MD, MPH, FACP Overview
Internal and Hospital Medicine
813-745-3134 The Psychosocial and Palliative Care Program is
bryan.bognar@moffitt.org engaged in clinical care, training and research designed
to address the emotional, social, spiritual and physical
needs of people being treated for cancer. Clinical
services are provided by an interdisciplinary team
P A L L I AT I V E C A R E P S Y C H I AT R Y composed of professionals with expertise in palliative
Sorin Buga, MD Margarita Bobonis Babilonia, MD care, psychiatry, clinical psychology, pharmacy, social
Internal Medicine Psychiatry work and chaplaincy. Psychosocial care is initiated with
813-745-6853 813-745-8483 a screening procedure designed to elicit patient and/
sorin.buga@moffitt.org margarita.bobonis@moffitt.org or family concerns, identify informational and resource
Shirley N. Codada, MD Shirley Kocur, MD needs and review psychological and social factors that
Internal Medicine; Hospice and Psychiatry could potentially interfere with the optimal delivery of
Palliative Care 813-745-8483 care. Additional components of the Psychosocial and
813-745-6853 shirley.kocur@moffitt.org Palliative Care Program include Integrative Medicine.
shirley.codada@moffitt.org Marguerite Pinard, MD Integrative Medicine at Moffitt offers many healing
Sahana Rajasekhara, MD Psychiatry
and wellness services, and integrates safe, effective
Internal Medicine; Geriatric Medicine 813-745-6052
813-745-6853 marguerite.pinard@moffitt.org therapies to complement conventional treatments
sahana.rajasekhara@moffitt.org and to improve the quality of life for patients during
and after cancer treatment. Integrative Medicine also
conducts research on therapies and incorporates
C L I N I C A L P SYC H O LO GY the latest advances into patient care to reduce the
Margaret Booth-Jones, PhD side effects and symptoms associated with cancer
Clinical Psychology treatments. The broad range of services include
813-745-6052 yoga, tai chi, meditation, guided imagery and
margaret.booth-jones@moffitt.org
relaxation therapy, inpatient and outpatient massage
Kristine A. Donovan, PhD, MBA therapy, acupuncture, nutrition and pharmaceutical
Clinical Psychology consultations.
813-745-6052
kristine.donovan@moffitt.org
Research
Paul B. Jacobsen, PhD
Clinical Psychology Research efforts are in palliative care and psychosocial
813-745-1810 oncology. The aims of the research program are to
paul.jacobsen@moffitt.org understand and influence human behavior for the
Sarah Rausch, PhD, LP purposes of promoting cancer prevention and control as
Director of Integrative Medicine well as symptom management. Current projects focus
813-745-6052 on developing psychosocial interventions to enhance
sarah.rausch@moffitt.org quality of life, identifying factors associated with
Lora M. A. Thompson, PhD support group participation and investigating processes
Clinical Psychology involved in patient decision making about cancer
813-745-6052 treatment. Additionally, Integrative Medicine trials
lora.thompson@moffitt.org designed to better understand outcomes for cancer
patients are offered; these trials utilize a variety of
complementary, alternative, and integrative therapies.
[ THESE PHYSICIANS ALSO SEE PATIENTS AT MOFFITT CANCER
CENTER’S SATELLITE LOCATION NEAR INTERNATIONAL PLAZA.
To refer a patient: 813-745-3980 or 1-888-860-2778, Mon-Fri, 8:00 am - 5:00 pm
Information about clinical trials: 813-745-4106
MOFFITT.org 19
20. RA D IATIO N O NCO LO GY D E PA RT M E N T
D E PA R T M E N T C H A I R
[ Craig W. Stevens, MD, PhD Overview
Radiation Oncology/Thoracic Oncology
813-745-8424 The Radiation Oncology Department provides highly
craig.stevens@moffitt.org specialized teams of physicians who have tumor-specific
expertise in the treatment of all tumor/organ sites and
a broad array of cutting-edge technologies. This allows
for expert radiotherapy treatment planning and delivery
MEMBERS Robert S. Lavey, MD, MPH that is personalized to each patient’s needs, as well as
Matthew C. Biagioli, MD Radiation Oncology/Pediatrics/ skilled management of radiation side effects. This care
Radiation Oncology/Brachytherapy Hematologic Services can be accessed by referral through the appropriate
Genitourinary Oncology 813-745-8424 multidisciplinary program, or by direct referral to
813-745-8424 robert.lavey@moffitt.org Radiation Oncology. Radiation treatment modalities
matthew.biagioli@moffitt.org [ Ravi Shridhar, MD, PhD include:
Jimmy J. Caudell, MD, PhD Radiation Oncology/
• 3-dimensional computerized radiation therapy
Radiation Oncology/Cutaneous, Gastrointestinal Oncology
813-745-8424 (3D CRT)
Head and Neck Oncology
813-745-3547 ravi.shridhar@moffitt.org • Intensity-modulated radiation therapy (IMRT)
jimmy.caudell@moffitt.org [ Craig W. Stevens, MD, PhD • Image-guided radiotherapy (IGRT) using
Prakash Chinnaiyan, MD Radiation Oncology/ TomoTherapy®, Novalis, Trilogy, TrueBeam™
Radiation Oncology/ Thoracic Oncology technologies
Neuro-Oncology 813-745-8424
craig.stevens@moffitt.org • Tumor motion management with 4D-CT and
813-745-8424
prakash.chinnaiyan@moffitt.org 4D-PET/CT, and respiratory gating
[ Michael B. Tomblyn, MD, MS
Candace R. Correa, MD, BS Radiation Oncology/ • Stereotactic radiotherapy (SRT) and stereotactic
Radiation Oncology/Breast Radiopharmaceuticals/Hematologic radiosurgery (SRS): to the brain, spine, lung, liver,
Oncology, Gynecologic Oncology Services pancreas and metastatic sites
813-745-4142 813-745-8424 • Advanced brachytherapy for many organ sites
candace.correa@moffitt.org michael.tomblyn@moffitt.org
• Accelerated partial breast irradiation (APBI) with
Thomas J. Dilling, MD Javier F. Torres-Roca, MD
Radiation Oncology/
brachytherapy or 3D CRT
Radiation Oncology/
Thoracic Oncology Genitourinary Oncology • IntraBeam® intraoperative breast radiotherapy
813-745-8424 813-745-8424 • Theraspheres® for the treatment of liver
thomas.dilling@moffitt.org javier.torresroca@moffitt.org metastases
[ Sophia Edwards-Bennett, MD, PhD Andrea “Andy” M. Trotti III, MD • Radiolabeled monoclonal antibody therapy of
Radiation Oncology/Breast Radiation Oncology/Cutaneous,
lymphoma: ibritumomab tiuxetan (Zevalin),
Oncology, Gynecologic Oncology Head and Neck Oncology
813-745-8424 tositumomab (Bexxar), and other novel agents for
813-745-8424
Sophia.EdwardsBennett@moffitt.org andy.trotti@moffitt.org the treatment of prostate cancer and metastases
Eleanor E.R. Harris, MD [ Richard B. Wilder, MS, MD, MBA
Clinical Director Radiation Oncology/
Radiation Oncology/Breast Genitourinary Oncology Research
Oncology, Gynecologic Oncology 813-745-8434 The Radiation Oncology Department participates as
813-745-8424 richard.wilder@moffitt.org a full-member institution of the Radiation Therapy
eleanor.harris@moffitt.org Hsiang-Hsuan Michael Yu, MD, ScM Oncology Group (RTOG) and has many national
Randy V. Heysek, MD Radiation Oncology/ protocols open for enrollment at Moffitt Cancer
Radiation Oncology/Prostate Neuro-Oncology Center. Moffitt faculty serve as principal investigators
Seed Implants 813-745-8424
michael.yu@moffitt.org or co-investigators on several RTOG trials and have
813-745-8424
investigator-initiated trials open in head and neck,
randy.heysek@moffitt.org
breast, lymphoma, gastrointestinal, brain and other
[ Sarah Hoffe, MD cancers. Numerous innovative investigator-initiated
Radiation Oncology/
trials are also open, with information available by
Gastrointestinal Oncology
Director of Physician Services, Moffitt request from the chair.
Cancer Center at International Plaza
813-745-8424
sarah.hoffe@moffitt.org
[ THESE PHYSICIANS ALSO SEE PATIENTS AT MOFFITT CANCER
CENTER’S SATELLITE LOCATION NEAR INTERNATIONAL PLAZA.
To refer a patient: 813-745-3980 or 1-888-860-2778, Mon-Fri, 8:00 am - 5:00 pm
Information about clinical trials: 813-745-4106
20 Moffitt Medical Group
